Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain
Budget Impact Analysis of Oral Fisiogen Ferro Forte® versus Intravenous Iron for the Management of Iron Deficiency in Chronic Kidney Disease in Spain
复制标题
DOI：
10.1007/s40261-018-0666-9
复制
发表时间：
2018-09-01
影响因子：
3.2
通讯作者：
Ascanio, Meritxell
中科院分区：
文献类型：
--
作者：
Darba, Josep;Ascanio, Meritxell
背景缺铁是慢性肾病（CKD）的常见并发症，与患者生活质量下降和其他临床并发症风险增加有关。铁剂治疗是CKD患者的基本治疗之一。Sucrosomial（R）口服铁允许Fisiogen Ferro Forte（R）用于所有对口服给药途径治疗不耐受的患者，目的本研究的主要目的是评估口服铁Fisiogen Ferro Forte（R）对西班牙CKD患者缺铁管理的经济影响。从西班牙医疗保健系统的角度来看，为2017-2020年期间因口服铁剂缺乏反应而成为静脉铁剂候选人的缺铁CKD患者开发了一个年度预算影响模型。CKD患者的三个亚组包括在分析中：透析前、腹膜透析和移植后。认为静脉内铁制剂Ferinject（R）、Venezol（R）和Feriv（R）是模型中使用的适当对照药物。从文献中获得了三个亚组患者CKD患病率的国家数据，并通过咨询肾脏病学家获得了与铁给药相关的药物利用和门诊住院的输入数据。肾病专家还被问及在医疗访问和监测测试期间使用的资源。根据每种铁剂治疗的单位成本和使用的资源，获得与每种产品相关的每位患者的总治疗成本，以估计增加使用Fisiogen Ferro Forte（R）对全球预算的影响。937，和195，842欧元超过4 years的透析前，腹膜透析，和移植后groups.Conclusions使用Fisiogen Ferro Forte（R）的增加导致西班牙国家卫生服务的总预算节省超过4 years的775，464欧元。
Background Iron deficiency is a frequent complication of chronic kidney disease (CKD) that is associated with a decrease in the quality of life of patients and an increase in the risk of other clinical complications. Iron therapy represents one of the fundamentals of patients with CKD. Sucrosomial (R) oral iron allows Fisiogen Ferro Forte (R) to be used in all patients who are intolerant to treatment by the oral route of administration, or who present with malabsorption of conventional oral iron preparations.Objective The main objective of this study was to assess the economic impact of the oral iron Fisiogen Ferro Forte (R) for the management of iron deficiency in CKD patients in Spain.Methods A 4-year budget impact model was developed for the period 2017-2020 for CKD patients with iron deficiency who were candidates for intravenous iron due to a lack of response to oral iron, from the perspective of the Spanish healthcare system. Three subgroups of CKD patients were included in the analysis: predialysis, peritoneal dialysis, and post-transplant. The intravenous iron formulations Ferinject (R), Venofer (R), and Feriv (R) were considered appropriate comparators to be used in the model. National data on the prevalence of CKD for the three subgroups of patients were obtained from the literature, and input data on drug utilization and outpatient hospitalizations associated with iron administration were obtained by consulting nephrologists. Nephrology experts were also asked about resources used during medical visits and monitoring tests. Based on the unit costs for each iron therapy and the resources used, the total treatment cost per patient associated with each product was obtained to estimate the global budget impact of increasing the use of Fisiogen Ferro Forte (R).Results The average annual budget savings due to an increase in Fisiogen Ferro Forte (R) and a decrease in intravenous iron have been estimated at Euro398,685, Euro180,937, and Euro195,842 over 4years for the predialysis, peritoneal dialysis, and post-transplant groups, respectively.Conclusions The increase in the use of Fisiogen Ferro Forte (R) leads to overall budget savings of Euro775,464 for the Spanish National Health Service over 4years.